$SHPH + $ATOS - Tuesday Watch
$SHPH — Friday’s surge was backed by strategic AI-driven expansion through the completed acquisition of https://t.co/vKw9Y3fF0O, adding automated molecular discovery tools to its oncology pipeline and supporting renewed financing momentum.
$ATOS — Shares jumped as the FDA awarded Orphan Drug Designation to (Z)-endoxifen for Duchenne Muscular Dystrophy, enhancing regulatory incentives and expanding the therapeutic narrative beyond breast cancer.
Watching volume and follow-through on Tuesday — positive sentiment could continue if traders build on these catalysts. DYOR and manage risk accordingly.